. Author manuscript; available in PMC: 2011 Mar 15.

Published in final edited form as: J Immunol. 2010 Feb 17;184(6):3250–3259. doi: 10.4049/jimmunol.0900722

TABLE IV.

Longitudinal IFN-γ ELISPOT Responses in IS and HSV-2+ Subjects^a

Subject	Study Day	# of SFC/10⁶ PBMC to each of the following HSV-2 Peptide Pools:
Subject	Study Day	gD-2	ICP0A	ICP0B	ICP22A	ICP27B	ICP4A	ICP4C	ICP4D	UL39A	UL39B	UL39C	UL19B	UL19-C	UL19D	UL25B	UL46B	UL47A	UL49	UL27A	UL29B	UL29C
IS2	0	215^b	105			70					90
	1,638	100
	1,945
IS4	0								115
	14								140
	34							60	185
	51								145
	350							90	155
IS5	0
	22								100		105				110					155
	343
	1,865								95
	1,927								95
IS6	0																		285
	51																		240
	155																		555
	450																		760			450
IS7	0		1,280	1,760
	161
	366												60
	707
IS9	0			1,340				115		845		15
	140							80
	163							110
	1,767							150
IS11	0													1,200
	57													520
	343													1,040
IS12	0				130					890											135
IS12	28
IS13	0
	302							205
	400
IS16	0										60
IS16	27										105
IS17	0						110
	364
	651										105
	764
IS19	0									60
	28		1,315	240							230							95
	56
	91
	406
	1,148		105							60
HSV-2+ A	0						119		74		329	154				96	179
HSV-2+ A	358						129		286		291						169
HSV-2+ B	0								200								163
HSV-2+ B	314																58
HSV-2+ C	0																	275
HSV-2+ C	440																	61
HSV-2+ D	0						83												130
HSV-2+ D	185																				130

PBMC were obtained from multiple blood draws from IS and HSV-2+ subjects and screened by IFN-γ ELISPOT using HSV-2 peptide pools. Only those HSV-2 peptide pools recognized by these subjects are displayed; no other HSV-2 peptide pools were positive in these 16 subjects. Blank cells represent a negative response to the peptide pool.

Shading denotes peptide pools positive from more than 1 blood draw in the same subject.